Breast Cancer Research and Treatment

, Volume 12, Issue 3, pp 307–310

Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels

  • G. Bertelli
  • P. Pronzato
  • D. Amoroso
  • M. P. Cusimano
  • P. F. Conte
  • G. Montagna
  • S. Bertolini
  • R. Rosso
Brief communication

Abstract

The possible estrogenic effects of tamoxifen on plasma lipids and antithrombin III levels were investigated in 91 breast cancer patients. Mean values of total, HDL and LDL cholesterol, triglycerides, glucose, uric acid, and antithrombin III were evaluated in 55 patients on adjuvant tamoxifen for at least 3 months and compared with those found in 36 patients on no therapy. Total cholesterol, LDL cholesterol, and antithrombin III levels were significantly lower in treated patients (p<0.05).

Our results support the hypothesis of a partial agonist action of this antiestrogen, although general clinical practice suggests that tamoxifen-related thrombotic events are rare.

Key words

tamoxifen adjuvant endocrine therapy plasma lipids antithrombin III 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rossner S, Wallgren A: Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 52: 339–346, 1984PubMedGoogle Scholar
  2. 2.
    Enck RE, Rios CN: Tamoxifen treatment of metastatic breast cancer and antithrombin III levels. Cancer 53: 2607–2609, 1984PubMedGoogle Scholar
  3. 3.
    Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18: 499–502, 1972PubMedGoogle Scholar
  4. 4.
    Dixon WJ: BMDP Statistical Software. University of California, Berkeley, 1981Google Scholar
  5. 5.
    Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustration of cases. Lancet 2: 102–104, 1896Google Scholar
  6. 6.
    Proceedings of the NIH Consensus Development Conference on Adjuvant Chemotherapy and Endocrine Therapy for Breast Cancer. NCI Monographs 1, 1986Google Scholar
  7. 7.
    Patterson JS, Battersby LA, Edwards DG: Review of the clinical pharmacology and international experience with tamoxifen in advanced breast cancer. Rev Endocrine Related Cancer, Suppl 9: 563–582, 1982Google Scholar
  8. 8.
    Jordan VC, Fritz NF, Tormey DC: Long-term adjuvant therapy with tamoxifen: effects on Sex Hormone Binding Globulin and Antithrombin III. Cancer Res 47: 4517–4519, 1987PubMedGoogle Scholar
  9. 9.
    Jacquot C, Graterol R, Bariety J, Capron L, Fiessinger JN: DES versus tamoxifen in advanced breast cancer (Letter). N Engl J Med 304: 1042, 1981Google Scholar
  10. 10.
    Nevasaari K, Heikkinen M, Taskinen PJ: Tamoxifen and thrombosis (Letter). Lancet 2: 946–947, 1978Google Scholar
  11. 11.
    Hendrick A, Subramanian VP: Tamoxifen and thromboembolism (Letter). JAMA 243: 514–515, 1980PubMedGoogle Scholar
  12. 12.
    Lipton A, Harvey HA, Hamilton RW: Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 68: 887–889, 1984PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1988

Authors and Affiliations

  • G. Bertelli
    • 1
  • P. Pronzato
    • 1
  • D. Amoroso
    • 1
  • M. P. Cusimano
    • 1
  • P. F. Conte
    • 1
  • G. Montagna
    • 1
    • 2
  • S. Bertolini
    • 1
    • 2
  • R. Rosso
    • 1
  1. 1.Istituto Nazionale per la Ricerca sul CancroDivisione di Oncologia MedicaGenovaItaly
  2. 2.Istituto Scientifico di Medicina InternaGenovaItaly

Personalised recommendations